

**Anti-Complement Factor D Reference Antibody (lampalizumab)
Recombinant Antibody
Catalog # APR10146****Specification****Anti-Complement Factor D Reference Antibody (lampalizumab) - Product Information**

Application	FC, Kinetics, Animal Model
Primary Accession	P00746
Reactivity	Human, Rabbit
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	143.8 KDa

Anti-Complement Factor D Reference Antibody (lampalizumab) - Additional Information**Target/Specificity**
Complement Factor D**Endotoxin**
< 0.001EU/ µg,determined by LAL method.**Conjugation**
Unconjugated**Expression system**
CHO Cell**Format**
Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.**Anti-Complement Factor D Reference Antibody (lampalizumab) - Protein Information****Name** CFD ([HGNC:2771](#))**Synonyms** DF, PFD**Function**
Serine protease that initiates the alternative pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system (PubMed:21205667, PubMed:22362762, PubMed:6769474, PubMed:874324, PubMed:9748277). In contrast to other complement pathways (classical, lectin and GZMK) that are directly activated by pathogens or antigen-antibody complexes, the alternative complement pathway is initiated by the spontaneous hydrolysis of complement C3 (PubMed:<a

[21205667](http://www.uniprot.org/citations/21205667), PubMed: [22362762](http://www.uniprot.org/citations/22362762), PubMed: [6769474](http://www.uniprot.org/citations/6769474), PubMed: [874324](http://www.uniprot.org/citations/874324)). The alternative complement pathway acts as an amplification loop that enhances complement activation by mediating the formation of C3 and C5 convertases (PubMed: [21205667](http://www.uniprot.org/citations/21205667), PubMed: [22362762](http://www.uniprot.org/citations/22362762), PubMed: [6769474](http://www.uniprot.org/citations/6769474), PubMed: [874324](http://www.uniprot.org/citations/874324)). Activated CFD cleaves factor B (CFB) when the latter is complexed with complement C3b, activating the C3 convertase of the alternative pathway (PubMed: [21205667](http://www.uniprot.org/citations/21205667), PubMed: [6769474](http://www.uniprot.org/citations/6769474), PubMed: [874324](http://www.uniprot.org/citations/874324), PubMed: [9748277](http://www.uniprot.org/citations/9748277)).

Cellular Location


Secreted

Anti-Complement Factor D Reference Antibody (lampalizumab) - Protocols


Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Anti-Complement Factor D Reference Antibody (lampalizumab) - Images



Anti-Complement Factor D Reference Antibody (lampalizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%



The purity of Anti-Complement Factor D Reference Antibody (lampalizumab) is more than 99.38%, determined by SEC-HPLC.



Immobilized human Complement Factor D, Fc at 2 µg/mL can bind Anti-Complement Factor D Reference Antibody (lampalizumab) $EC_{50} = 0.02371$ µg/mL